---
title: Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination
nct_id: NCT05043168
overall_status: COMPLETED
sponsor: University of Giessen
study_type: OBSERVATIONAL
primary_condition: Covid19
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05043168.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05043168"
ct_last_update_post_date: 2022-05-19
last_seen_at: "2026-05-12T06:51:18.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Kidney Histopathology After COVID-19 and SARS-CoV-2 Vaccination

**Official Title:** Kidney Histopathological Features in Patients After COVID-19 and SARS-CoV-2 Vaccination

**NCT ID:** [NCT05043168](https://clinicaltrials.gov/study/NCT05043168)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 42
- **Lead Sponsor:** University of Giessen
- **Collaborators:** Universitätsklinikum Hamburg-Eppendorf
- **Conditions:** Covid19, Vaccination Reaction
- **Start Date:** 2021-09-18
- **Completion Date:** 2022-05-17
- **CT.gov Last Update:** 2022-05-19

## Brief Summary

The study aims to summarize kidney histopathological findings in patients with coronavirus disease 2019 (COVID-19) and post-severe acute respiratory syndrome-coronavirus-type 2 (SARS-CoV-2) vaccination.

## Detailed Description

The SARS-CoV-2 pandemic has had substantial global morbidity and mortality. While COVID-19 is most commonly characterized as a respiratory illness, extrapulmonary manifestations are a prominent part its clinical spectrum. Kidney disease is a common finding in COVID-19, and has also been rarely described after SARS-CoV-2 vaccination. The main objective of this study is to summarize kidney histopathological findings in patients with COVID-19 and post-SARS-COV-2 vaccination, in whom native kidney biopsy was performed and samples were obtained by the Nephropathology Section, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Inclusion Criteria:

* being diagnosed with COVID-19 when kidney biopsy was performed
* history of recent homologous or heterogenous vaccine regimen comprising either vector-based vaccines or messenger ribonucleic acid-based vaccines

Exclusion Criteria:

* Patient refuses participation
```

## Arms

- **Patients with COVID-19** — Polymerase Chain Reaction-positive SARS-CoV-2 infection
- **Patients post-SARS-CoV-2 vaccination** — Onset of kidney disease potentially relatable to SARS-CoV-2 vaccination based on clinical grounds

## Primary Outcomes

- **Frequency of histopathologically confirmed glomerular and tubulointerstitial diseases** _(time frame: Kidney biopsy obtained during COVID-19 disease and up to 3 months after SARS-CoV-2 vaccination)_

## Locations (1)

- University Clinic Giessen and Marburg - Campus Giessen, Giessen, Hesse, Germany

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.university clinic giessen and marburg - campus giessen|giessen|hesse|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05043168.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05043168*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*